CSF3 and anemia (phenotype): The treatment was poorly tolerated with grade 4 neutropenia and grade 2 anemia after the first cycle and grade 4 neutropenia after the second cycle with 50% dose reduction and secondary prophylaxis with granulocyte colony-stimulating factor (G-CSF).